Expansion of the Management Board of M1 Kliniken AG

M1 Kliniken AG (ISIN: DE000A0STSQ8) announces that the sale of HAEMATO Pharm GmbH by its majority holding, HAEMATO AG (85%), to the PHOENIX group was successfully completed effective as of the end of January 31, 2026.

Following the fulfillment of all closing conditions, including the necessary antitrust approvals, the transaction has now been legally consummated. Consequently, HAEMATO Pharm GmbH will be deconsolidated from the scope of consolidation of both HAEMATO AG and M1 Kliniken AG.

With the successful closing of this transaction, M1 Kliniken AG continues to consistently pursue its strategic focus and strengthens its positioning as a leading global, vertically integrated pure-play provider of medical aesthetics.